Melatonin protects against behavioral deficits, dopamine loss and oxidative stress in homocysteine model of Parkinson's disease

Life Sci. 2018 Jan 1:192:238-245. doi: 10.1016/j.lfs.2017.11.016. Epub 2017 Nov 11.

Abstract

Aim: Hyperhomocysteinemia and homocysteine (Hcy) mediated dopaminergic neurotoxicity is a matter of concern in the pathophysiology of Parkinson's disease (PD). Our previous study established the involvement of oxidative stress in the substantia nigra (SN) of Hcy rat model of PD; however, the role of antioxidants, such as melatonin, was not tested in this model.

Main methods: Melatonin (10, 20 and 30mg/kg, i.p.) was administered to rats injected with Hcy in right SN (1.0μmol in 2μl saline) to investigate its potency in attenuating the behavioral abnormalities, dopamine depletion and oxidative stress prompted by Hcy.

Key findings: Treatment of melatonin protected against nigral dopamine loss and replenished the striatal dopamine loss that resulted in amelioration of rotational behavioral bias in Hcy denervated animals. Melatonin administration significantly improved mitochondrial complex-I activity and protected the SN neurons from the toxic insults of oxidative stress induced by Hcy. Amelioration of oxidative stress by melatonin in Hcy-infused SN was bought by dose-dependently scavenging of hydroxyl radicals, restoration of glutathione level and elevation in the activity of antioxidant enzymes.

Significance: The observations bring into light the significant neuroprotective potentials of melatonin in Hcy model of PD which is attributed to the attenuation of oxidative stress in SN.

Keywords: Antioxidant; Complex-I; Dopamine; Hydroxyl radical; Neuroprotection; Rotational bias.

MeSH terms

  • Animals
  • Antioxidants / therapeutic use*
  • Behavior, Animal / drug effects*
  • Catecholamines / metabolism
  • Dopamine / metabolism*
  • Dopaminergic Neurons / drug effects
  • Electron Transport Complex I / drug effects
  • Free Radicals / metabolism
  • Homocysteine* / administration & dosage
  • Male
  • Melatonin / therapeutic use*
  • Microinjections
  • Neuroprotective Agents / therapeutic use*
  • Oxidative Stress / drug effects*
  • Parkinson Disease, Secondary / chemically induced
  • Parkinson Disease, Secondary / prevention & control*
  • Parkinson Disease, Secondary / psychology*
  • Rats
  • Rats, Sprague-Dawley
  • Substantia Nigra / drug effects
  • Substantia Nigra / metabolism

Substances

  • Antioxidants
  • Catecholamines
  • Free Radicals
  • Neuroprotective Agents
  • Homocysteine
  • Electron Transport Complex I
  • Melatonin
  • Dopamine